Methotrexat-Versorgung vor dem Einsatz von Biologika bei rheumatoider Arthritis: Eine Analyse der Leitliniengerechtigkeit

BACKGROUND: With the introduction of biologics the treatment landscape for patients with rheumatoid arthritis (RA) has rapidly expanded; however, according to German and European treatment guidelines the use of biologic disease-modifying antirheumatic drugs (bDMARD) is only indicated after insuffici...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardey, Nicolas, Zeidler, Jan, Nellenschulte, Tim Fritz, Stahmeyer, Jona T., Hoeper, Kirsten, Witte, Torsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Originalien
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495498/
https://www.ncbi.nlm.nih.gov/pubmed/34545429
http://dx.doi.org/10.1007/s00393-021-01086-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495498/
https://www.ncbi.nlm.nih.gov/pubmed/34545429
http://dx.doi.org/10.1007/s00393-021-01086-0

Ejemplares similares